The Associated Press interviewed Terry Heiman-Patterson, MD, Professor of Neurology at the Lewis Katz School of Medicine at Temple University and Director of the Temple MDA/ALS Center of Hope, for an article about Relyvrio. Relyvrio is only the third medication approved in the United States for ALS, or amyotrophic lateral sclerosis. Fortune picked up the Associated Press article.
Weather Alert: Temple Health remains open, though some appointments or services may be adjusted. Patients will be contacted directly if their visit is affected. Please check TempleHealth.org for updates and monitor myTempleHealth for changes to scheduled appointments.
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH